Mechanism of ITGB2 in Osteoclast Differentiation in Osteoarthritis
Cell Proliferation · 2025
DOI: 10.1111/cpr.70107 ↗At a glance
Journal article in Cell Proliferation, 2025. Written by Yang Yang and 16 co-authors. Institution: The Third Ward of Orthopaedic Department, Institute of Osteoarthropathy, Institute of Medical Sciences, General Hospital of Ningxia Medical Universit…. Major MEDLINE topics: Osteoarthritis, Cell Differentiation, Osteoclasts, CD18 Antigens. Cited 1 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Key R&D Project of Autonomous Region, Autonomous Region Major Scientific and Technological Achievements Transformation Project.
Abstract (original language)
Transcriptomics studies have identified integrin receptor β2 subunit (ITGB2) as a core gene in osteoarthritis (OA), strongly linked to osteoclast function in the subchondral bone. However, the mechanism through which ITGB2 regulates osteoclast function in OA remains unclear. In this study, we found that ITGB2 was negatively correlated with ITGB1 in the human subchondral bone. Proteomic analysis indicated that integrin binding is crucial in OA subchondral bone, with ITGB2 identified as a significantly upregulated protein in OA. In vitro experiments using immunoprecipitation and bimolecular fluorescence complementation revealed that ITGB2, but not ITGB1, directly interacts with Rac1 during osteoclast differentiation. Activated Rac1 promotes osteoclast differentiation and bone resorption through several mechanisms. ITGB2 knockdown reduced Rac1‐GTP levels and increased ITGB1 expression. ITGB2 inhibition reduced actin ring formation and microtubule migration to the cell edge during osteoclast differentiation. Additionally, overexpression of ITGB1 in ITGB2‐knockdown cells not only further suppressed ITGB2 expression but also exacerbated the inhibition of osteoclast differentiation. In a DMM mouse model, ITGB2 was associated with osteoclast activity in the subchondral bone. ITGB2 knockdown significantly reduced bone resorption and slowed OA progression by inhibiting osteoclastogenesis. In conclusion, our study identified a novel mechanism for the reciprocal regulation of integrin subunits. Moreover, inhibition of the ITGB2 signalling pathway slows subchondral bone remodelling in osteoarthritis by inhibiting osteoclast differentiation, offering a potential strategy for targeted therapeutic interventions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The Third Ward of Orthopaedic Department, Institute of Osteoarthropathy, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China.
- Ningxia Key Laboratory of Clinical and Pathogenic Microbiology, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China.
ORCID profiles: Qunhua Jin
Funding
- National Natural Science Foundation of China
- Key R&D Project of Autonomous Region
- Autonomous Region Major Scientific and Technological Achievements Transformation Project
- Ningxia Medical University General Hospital "Medical Engineering Special"
Cite
APA
Yang, Y., Sun, R., Lan, Z., Ma, Q., Wu, G., Xue, D., Chen, Z., Su, Y., Ma, Y., Chen, X., Yan, J., Ma, L., He, X., Tian, K., Ma, X., Lin, X., & Jin, Q. (2025). Mechanism of ITGB2 in Osteoclast Differentiation in Osteoarthritis. Cell Proliferation. https://doi.org/10.1111/cpr.70107
Vancouver
Yang Y, Sun R, Lan Z, Ma Q, Wu G, Xue D, et al. Mechanism of ITGB2 in Osteoclast Differentiation in Osteoarthritis. Cell Proliferation. 2025. doi:10.1111/cpr.70107
BibTeX
@article{Yang2025,
author = {Yang, Yang and Sun, Rui and Lan, Zhibin and Ma, Qi and Wu, Gang and Xue, Di and Chen, Zhirong and Su, Yajing and Ma, Ye and Chen, Xiaolei and Yan, Jiangbo and Ma, Long and He, Xiaoxin and Tian, Kuanmin and Ma, Xiaoyi and Lin, Xue and Jin, Qunhua},
title = {Mechanism of ITGB2 in Osteoclast Differentiation in Osteoarthritis},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.70107}
}
EUVIMED